不同剂量分割放疗IIIB期非小细胞肺癌的疗效及毒性比较
Analysis of Efficacy and Toxicity of Different Doses Fraction of Radiotherapy for Stage IIIB Non-Small Cell Lung Cancer

作者: 葛 琴 * , 蔡 晶 , 谢国栋 , 杨百霞 , 金建华 , 储开岳 , 赵季忠 , 俞岑明 , 葛彬彬 , 曹 飞 :南通市肿瘤医院放疗科,江苏 南通;

关键词: 非小细胞肺癌放射治疗剂量分割Non-Small Cell Lung Cancer Radiation Therapy Dose Fractionation

摘要:
目的:比较采用不同剂量分割放疗IIIB期非小细胞肺癌后的疗效及毒性反应。方法:40例IIIB期非小细胞肺癌行三维适形放疗患者,大剂量分割组20例(PTR组)和常规剂量分割组20例(CRT组),每次治疗前行CBCT扫描验证计划,所有患者均完成处方剂量。计算并比较两组患者放疗后近期疗效及放疗结束3个月内不良反应发生情况。结果:PTR组胸部病灶达CR或PR占40% (8/20),SD患者占35% (7/20),PD的患者占25% (5/20)。CRT组胸部病灶达CR或PR占30% (6/20),SD患者占35% (7/20),PD的患者占35% (7/20)。所有患者均未出现3~4级不良反应,差异无统计学意义(P > 0.05)。结论:在IIIB期非小细胞肺癌适形放疗中,宜采用大分割放疗,从而提高局控率,缩短疗程,节省时间和资源。

Abstract: Objective: To compare different doses of radiotherapy in phase IIIB non-small cell lung cancer efficacy and toxicity. Methods: 40 cases of phase IIIB non-small cell lung cancer patients who were treated by three-dimensional conformal radiotherapy were randomly divided into high-dose fraction group (PTR) and conventional fraction group (CRT). All patients completed prescription dose with a CBCT scan validation program before each treatment. The short-term effects of radiotherapy and the incidence of adverse events within 3 months after radiotherapy were calculated and compared between the two groups. Results: PTR Group chest lesions of CR or PR accounted for 40% (8/20), SD patients accounted for 35% (7/20), and PD patients accounted for 25% (5/20). CRT Group chest lesions of CR or PR accounted for 30% (6/20), SD patients accounted for 35% (7/20), and PD patients accounted for 35% (7/20). No patient experienced grade 3 to 4 adverse events, with no significant difference (P > 0.05). Conclusion: High-dose fraction radiation therapy should be selected in the IIIB non-small cell lung cancer conformal radiotherapy, because it can improve the local control rate, shorten the course of treatment, and save time and resources.

文章引用: 葛 琴 , 蔡 晶 , 谢国栋 , 杨百霞 , 金建华 , 储开岳 , 赵季忠 , 俞岑明 , 葛彬彬 , 曹 飞 (2016) 不同剂量分割放疗IIIB期非小细胞肺癌的疗效及毒性比较。 世界肿瘤研究, 6, 15-19. doi: 10.12677/WJCR.2016.62003

参考文献

[1] 殷蔚柏, 余子豪. 肿瘤放射治疗学[M]. 第4版. 北京: 中国协和医科大学出版社, 2008: 573-608.

[2] 袁葆琳, 张涛. 三维适形放射治疗(3DCRT)非小细胞肺癌临床研究[J]. 中国肿瘤临床, 2012( 6): 306-309.

[3] Le Péchoux, C. (2011) Role of Post-operative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data. The Oncologist, 16, 672-681. http://dx.doi.org/10.1634/theoncologist.2010-0150

[4] Fairchild, A., Harris, K., Barnes, E., et al. (2008) Palliative Thoracic Radiotherapy for Lung Cancer: A Systematic Review. Journal of Clinical Oncology, 26, 4001-4011. http://dx.doi.org/10.1200/JCO.2007.15.3312

[5] Bezjak, A., Dixon, P., Brundage, M., et al. (2012) Randomized Phase III Trial of Single versus Fractionated Thoracic Radiation in the Palliation of Patients with Lung Cancer (NCIC CTG SC.15). International Journal of Radiation Oncology*Biology*Physics, 54, 719-728. http://dx.doi.org/10.1016/S0360-3016(02)02989-9

[6] 刘维帅, 赵陆军, 刘志艳, 等. 进展期非小细胞肺癌短疗程大分割姑息放疗疗效分析[J]. 中国肿瘤临床, 2013, 40(20): 1240-1243.

[7] 沈文斌, 祝淑钗, 高红梅, 等. 三维适形大分割放射治疗局部中晚期非小细胞肺癌的不良反应与长期生存分析[J]. 肿瘤防治研究, 2012, 39(5): 577-581.

[8] Beli, I., Koukourakis, G., Platoni, K., et al. (2010) Hypofractionated Radiotherapy in Non Small Cell Lung Cancer: A Review of the Current Literature. Reviews on Recent Clinical Trials, 5, 103-111. http://dx.doi.org/10.2174/157488710791233608

[9] Salama, J.K. and Vokes, E.E. (2013) New Radiotherapy and Chemoradiotherapy Approaches for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 1029-1038. http://dx.doi.org/10.1200/JCO.2012.44.5064

[10] Partridge, M., Ramos, M., Sardaro, A., et al. (2011) Dose Escalation for Non-Small Cell Lung Cancer: Analysis and Modelling of Published Literature. Radiotherapy & Oncology, 99, 6-11. http://dx.doi.org/10.1016/j.radonc.2011.02.014

[11] Taremi, M., Hope, A., Dahele, M., et al. (2012) Stereotactic Body Radiotherapy for Medically Inoperable Lung Cancer: Prospective, Single-Center Study of 108 Consecutive Patients. International Journal of Radiation Oncology*Biology* Physics, 82, 967-973. http://dx.doi.org/10.1016/j.ijrobp.2010.12.039

[12] Champeaux-Orange, E., Wachter, T., Bouscayrol, H., et al. (2011) Stereotactic Radiotherapy for Stage I and II Lung Cancer: A Study of 33 Patients. Cancer/Radiothérapie, 15, 192-196. http://dx.doi.org/10.1016/j.canrad.2010.10.002

[13] Turzer, M., Brustugun, O.T., Waldeland, E., et al. (2011) Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity. Case Reports in Oncology, 4, 25-34. http://dx.doi.org/10.1159/000324113

[14] Andrstschke, N., Zimmermann, F., Boehm, E., et al. (2011) Stereotactic Radiotherapy of Histologically Proven Inoperable Stage I Non-Small Cell Lung Cancer: Patterns of Failure. Radiotherapy & Oncology, 101, 245-249. http://dx.doi.org/10.1016/j.radonc.2011.06.009

[15] Ausborn, N.L., Le, Q.T., Bradley, J.D., et al. (2012) Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology*Biology*Physics, 83, e453- e464. http://dx.doi.org/10.1016/j.ijrobp.2012.01.056

分享
Top